Effectiveness and Safety of Perampanel in Refractory Focal Epilepsy: Real-World Evidence From a Chinese Cohort.

ABSTRACT:

Objective

To evaluate the effectiveness and safety of perampanel (PER) as an add-on treatment in patients with refractory focal epilepsy.

Methods

This single-center, retrospective observational study consecutively enrolled patients with refractory focal epilepsy who initiated PER as adjunctive therapy between September 2020 and October 2021. The primary outcomes included PER effectiveness (≥ 50% seizure reduction), treatment retention rates, and adverse event (AE) profiles, systematically evaluated at 3-, 6-, and 12-month follow-up intervals.

Results

This study included 190 patients (median age 27 years; 51.6% female). At 3/6/12-month follow-ups, response rates were 65.5%/64.9%/66.1%, seizure-free rates 26.2%/26.2%/26.8%, and retention rates 88.4%/69.0%/66.8%, respect

SUBMITTER: Yi T 

PROVIDER: S-EPMC12571969 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature